<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Musculoskeletal</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Changchun Genescience Pharmaceuticals divulges new PTHR1 agonists</title>
      <description>
        <![CDATA[Changchun Genescience Pharmaceuticals Co. Ltd. has reported new parathyroid hormone receptor 1 (PTHR1) agonists potentially useful for the treatment of arthritis, fracture, hyperphosphatemia and more.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730524</guid>
      <pubDate>Mon, 20 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730524-changchun-genescience-pharmaceuticals-divulges-new-pthr1-agonists</link>
    </item>
    <item>
      <title>Roche plots route to EMA approval for DMD gene therapy</title>
      <description>
        <![CDATA[Roche Holding AG is making good on its promise to try and convince the EMA of the benefits of Elevidys (delandistrogene moxeparvovec), announcing a further global phase III trial of the Duchenne muscular dystrophy gene therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730404</guid>
      <pubDate>Fri, 17 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730404-roche-plots-route-to-ema-approval-for-dmd-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-strand-of-DNA.webp?t=1709153170" type="image/jpeg" medium="image" fileSize="103448">
        <media:title type="plain">Green strand of DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Regeneration in mammals is controlled by environmental conditions</title>
      <description>
        <![CDATA[The loss of regenerative capacity in mammals over the course of evolution may be linked to certain environmental conditions rather than to a genetic limitation. Tissue stiffness around an amputated area, oxygen availability, or epigenetic regulation could determine this ability, according to two simultaneously published but independent studies published in <em>Science</em>, as reported by <em>BioWorld</em> yesterday.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730344</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730344-regeneration-in-mammals-is-controlled-by-environmental-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Tsissios-regenerating-tadpole-limb-adw8526-hero.webp?t=1775828910" type="image/jpeg" medium="image" fileSize="1401255">
        <media:title type="plain">Confocal cross section of a regenerating tadpole limb. </media:title>
        <media:description type="plain">Confocal cross section of a regenerating tadpole limb, highlighting cellular boundaries (red) and nuclei (grey). Credit: Georgios Tsissios.</media:description>
      </media:content>
    </item>
    <item>
      <title>Regeneration in mammals is controlled by environmental conditions</title>
      <description>
        <![CDATA[The loss of regenerative capacity in mammals over the course of evolution may be linked to certain environmental conditions rather than to a genetic limitation. Tissue stiffness around an amputated area, oxygen availability, or epigenetic regulation could determine this ability, according to two simultaneously published but independent studies published in <em>Science</em> today.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730322</guid>
      <pubDate>Thu, 09 Apr 2026 14:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730322-regeneration-in-mammals-is-controlled-by-environmental-conditions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Tsissios-regenerating-tadpole-limb-adw8526-hero.webp?t=1775828910" type="image/jpeg" medium="image" fileSize="1401255">
        <media:title type="plain">Confocal cross section of a regenerating tadpole limb. </media:title>
        <media:description type="plain">Confocal cross section of a regenerating tadpole limb, highlighting cellular boundaries (red) and nuclei (grey). Credit: Georgios Tsissios.</media:description>
      </media:content>
    </item>
    <item>
      <title>Renovare launches to advance osteoarthritis therapies</title>
      <description>
        <![CDATA[Renovare Therapeutics Inc. has announced its formal launch from stealth mode with a focus on developing regenerative therapies for musculoskeletal diseases, including osteoarthritis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730192</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730192-renovare-launches-to-advance-osteoarthritis-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Inflammatory/Joint-pain2.webp?t=1642802876" type="image/png" medium="image" fileSize="238323">
        <media:title type="plain">Joint pain </media:title>
      </media:content>
    </item>
    <item>
      <title>Fortitude unveils lead program for axial spondyloarthritis</title>
      <description>
        <![CDATA[Fortitude Biomedicines Inc. has disclosed that its lead program, FORT-202, is a first-in-class T-cell-targeting bispecific antibody for the potential treatment of axial spondyloarthritis. As a bispecific antibody, FORT-202 is designed to address multiple disease-causing pathways and is expected to significantly improve therapeutic efficacy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730188</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730188-fortitude-unveils-lead-program-for-axial-spondyloarthritis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Spinal-cord.webp?t=1601907299" type="image/png" medium="image" fileSize="343619">
        <media:title type="plain">Spinal cord</media:title>
      </media:content>
    </item>
    <item>
      <title>Ernexa eyes clinic with ERNA-101 for ovarian cancer</title>
      <description>
        <![CDATA[Ernexa Therapeutics Inc. is advancing its lead program, ERNA-101, toward an IND submission in the third quarter of this year and the initiation of a first-in-human trial in the fourth quarter for the treatment of platinum-resistant ovarian cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730095</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730095-ernexa-eyes-clinic-with-erna-101-for-ovarian-cancer</link>
    </item>
    <item>
      <title>Assay what? Eyes on Pepgen’s DM1 phase II</title>
      <description>
        <![CDATA[Phase II data disclosed March 31 by Pepgen Inc. in myotonic dystrophy type 1 (DM1) hobbled the stock but might have been much different if not for one outlier in the 5-mg/kg multiple ascending dose cohort of the ongoing phase II Freedom2-DM1 trial – and Wall Street is pondering what the hitch means for the Boston-based firm as well as the competitive space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729979</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729979-assay-what-eyes-on-pepgens-dm1-phase-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Limb-exam.webp?t=1613158518" type="image/png" medium="image" fileSize="400910">
        <media:title type="plain">Limb exam</media:title>
      </media:content>
    </item>
    <item>
      <title>PTBP1 identified as potential target for Duchenne muscular dystrophy</title>
      <description>
        <![CDATA[Researchers from the China Pharmaceutical University and Guangdong Pharmaceutical University (China) have unveiled the crucial role of the alternative splicing of E2A in myogenic progression and demonstrated that PTBP1, by controlling E2A alternative splicing, is a critical regulator of myogenesis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729724</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729724-ptbp1-identified-as-potential-target-for-duchenne-muscular-dystrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Musculoskeletal-skeletal-muscle-fiber.webp?t=1672846692" type="image/png" medium="image" fileSize="2032839">
        <media:title type="plain">Light micrograph of skeletal muscle.</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729710</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729710-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>SFL-0821 shows promise for facioscapulohumeral muscular dystrophy</title>
      <description>
        <![CDATA[Facioscapulohumeral muscular dystrophy (FSHD) is a muscle wasting disease caused by aberrant expression of double homeobox protein 4 (DUX4). When DUX4 is activated in skeletal muscle, it triggers myocyte cell death after several transcriptional changes, thus genetic DUX4 silencing arises as a promising approach for treating FHSD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729673</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729673-sfl-0821-shows-promise-for-facioscapulohumeral-muscular-dystrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Motor-neuron-muscle.webp?t=1675957121" type="image/png" medium="image" fileSize="1756485">
        <media:title type="plain">Illustration of motor neuron connecting to muscle fiber</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea Research Institute of Chemical Technology reports LATS1 and LATS2 inhibitors</title>
      <description>
        <![CDATA[Korea Research Institute of Chemical Technology has prepared and tested new serine/threonine-protein kinase LATS1 and LATS2 inhibitors reported to be useful for the treatment of sarcopenia, muscular dystrophy, inflammatory myopathy, congenital myopathy, myotonia, myofascial pain syndrome, motor neuron diseases and muscle injury.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729639</guid>
      <pubDate>Fri, 13 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729639-korea-research-institute-of-chemical-technology-reports-lats1-and-lats2-inhibitors</link>
    </item>
    <item>
      <title>MDA: Vinay away, AA in play for Regenxbio gene therapy?</title>
      <description>
        <![CDATA[With top-line pivotal data with gene therapy RGX-202 for Duchenne muscular dystrophy (DMD) due in the next quarter, Regenxbio Inc. rolled out positive interim data from the phase I/II Affinity trial at the Muscular Dystrophy Association Clinical and Scientific Conference (MDA) in Orlando, Fla., where Bridgebio Pharma Inc., Capricor Therapeutics Inc., and Solid Biosciences Inc. also had clinical findings to talk about.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729478</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729478-mda-vinay-away-aa-in-play-for-regenxbio-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Muscle-anatomy-dna-research.webp?t=1732551219" type="image/jpeg" medium="image" fileSize="103105">
        <media:title type="plain">Illustration of man holding magnifying glass to human body model showing muscle anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729467</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729467-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA ‘blacklist’ in DMD? Legislator slams PTC turndown</title>
      <description>
        <![CDATA[The strife-marked Duchenne muscular dystrophy (DMD) space drew forth another outspoken political figure in the shape of Sen. Ron Johnson (R-Wisc.), who said he was “enraged” by the U.S. FDA’s refusal to consider PTC Therapeutics Inc.’s Translarna (ataluren) for the treatment of nonsense mutation disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729463</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729463-fda-blacklist-in-dmd-legislator-slams-ptc-turndown</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-magnifying-glass.webp?t=1773260641" type="image/jpeg" medium="image" fileSize="497756">
        <media:title type="plain">Photo of magnifying glass inspecting the text FDA</media:title>
      </media:content>
    </item>
    <item>
      <title>Japan approves first iPSC therapy for Parkinson’s disease </title>
      <description>
        <![CDATA[Japan has approved the world’s first therapies derived from induced pluripotent stem cells (iPSCs), marking a major milestone for regenerative medicine and, potentially, a turning point in treating Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729586</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729586-japan-approves-first-ipsc-therapy-for-parkinsons-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Induced-pluripotent-stem-cells.webp?t=1652824580" type="image/png" medium="image" fileSize="340449">
        <media:title type="plain">Induced pluripotent stem cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Japan approves first iPSC therapy for Parkinson’s disease </title>
      <description>
        <![CDATA[Japan has approved the world’s first therapies derived from induced pluripotent stem cells (iPSCs), marking a major milestone for regenerative medicine and, potentially, a turning point in treating Parkinson’s disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729360</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729360-japan-approves-first-ipsc-therapy-for-parkinsons-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Induced-pluripotent-stem-cells.webp?t=1652824580" type="image/png" medium="image" fileSize="340449">
        <media:title type="plain">Induced pluripotent stem cells</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA curtails Pepgen’s Freedom2 operate in DM1 </title>
      <description>
        <![CDATA[Pepgen Inc. is forging ahead with tests of PGN-EDODM1 in other territories after the U.S. FDA placed a partial hold on the Freedom2-DM1 phase II trial, a multiple ascending-dose, randomized, placebo-controlled experiment in myotonic dystrophy type 1 (DM1).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729340</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729340-fda-curtails-pepgens-freedom2-operate-in-dm1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Person-holding-weight-with-assistance.webp?t=1718227548" type="image/jpeg" medium="image" fileSize="117825">
        <media:title type="plain">Person holding weight with assistance</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies </title>
      <description>
        <![CDATA[Innovacell Inc. launched a ¥14.16 billion (US$91.2 million) stock sale on the Tokyo Stock Exchange Feb. 24, ending a near two-year lull of biotech listings in Japan while signaling a dynamic year ahead for cell-based therapeutics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729194</guid>
      <pubDate>Tue, 24 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729194-innovacells-91m-tokyo-ipo-to-fund-incontinence-cell-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Glass-yen-yuan-symbol.webp?t=1664308599" type="image/png" medium="image" fileSize="289038">
        <media:title type="plain">Glass yen/yuan symbol</media:title>
      </media:content>
    </item>
    <item>
      <title>AI transforming med tech in 2026; clinical need drives investments</title>
      <description>
        <![CDATA[Med-tech companies with an AI component in their solutions will certainly find investors willing to back them. AI after all, is being used to develop more effective, smarter technologies. However, investors will only deploy capital into innovations that address genuine clinical needs. The aging population is driving interest in devices targeting cardiovascular and musculoskeletal disorders, and other solutions geared toward neurological conditions, women’s health and diagnostics are also attracting investor attention.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729072</guid>
      <pubDate>Wed, 18 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729072-ai-transforming-med-tech-in-2026-clinical-need-drives-investments</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-medical-illustration.webp?t=1686858173" type="image/jpeg" medium="image" fileSize="216630">
        <media:title type="plain">AI medical illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>T cells store lipids and die in rheumatoid arthritis joints</title>
      <description>
        <![CDATA[In the inflamed joints of rheumatoid arthritis, CD4+ T lymphocytes accumulate lipid droplets that make them vulnerable and promote their death, thereby amplifying joint inflammation. A study led by scientists at Mayo Clinic and Stanford University suggests that blocking the formation of these lipid droplets or their contents could offer a therapeutic strategy for this condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728915</guid>
      <pubDate>Wed, 18 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728915-t-cells-store-lipids-and-die-in-rheumatoid-arthritis-joints</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Hand-wrist-inflammation-arthritis-joint-pain.webp?t=1771431082" type="image/jpeg" medium="image" fileSize="393611">
        <media:title type="plain">X-ray image of hand and wrist</media:title>
      </media:content>
    </item>
    <item>
      <title>Human organoid mimics cancer-induced cachexia </title>
      <description>
        <![CDATA[The variety of organoids that can be developed in vitro is enabling major advances. Depending on the type of tissues and the research goals, these small 3D cell-based structures that mimic real tissue offer certain advantages over animal models. Scientists at the University of Padova in Italy have created human neuromuscular organoids to reproduce cancer-induced muscle cachexia, a condition that murine models do not accurately replicate.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728897</guid>
      <pubDate>Tue, 17 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728897-human-organoid-mimics-cancer-induced-cachexia</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/organoids-petri-dish.webp?t=1709922088" type="image/jpeg" medium="image" fileSize="115495">
        <media:title type="plain">3D illustration of organoid models in a petri dish</media:title>
        <media:description type="plain">3D illustration of organoid models in a petri dish</media:description>
      </media:content>
    </item>
    <item>
      <title>Dwarfism golden gate? Bridgebio’s infigratinib phase III hits</title>
      <description>
        <![CDATA[Bridgebio Pharma Inc. kept the phase III wins coming, this time with positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib, designed to inhibit FGFR3 signaling in children with achondroplasia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728846</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728846-dwarfism-golden-gate-bridgebios-infigratinib-phase-iii-hits</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/Toddler-and-adult.webp?t=1770933930" type="image/jpeg" medium="image" fileSize="578058">
        <media:title type="plain">Toddler walking with adult</media:title>
      </media:content>
    </item>
    <item>
      <title>Genentech plans NDA for multiple sclerosis pill with study win</title>
      <description>
        <![CDATA[Genentech Inc. is covering more bases in multiple sclerosis, with its latest swing on fenebrutinib hitting a rare phase III noninferiority win against Ocrevus (ocrelizumab) in primary progressive multiple sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728716</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728716-genentech-plans-nda-for-multiple-sclerosis-pill-with-study-win</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Glass-of-water-and-tablets.webp?t=1764799994" type="image/jpeg" medium="image" fileSize="854423">
        <media:title type="plain">Glass of water and tablets</media:title>
      </media:content>
    </item>
    <item>
      <title>S100a8 knockdown mitigates symptoms in Marfan syndrome</title>
      <description>
        <![CDATA[Researchers from the University of São Paulo (Brazil) first proposed using eccentric training as a promising intervention to address musculoskeletal impairments associated with Marfan syndrome. Eccentric training is a form of resistance exercise that focuses on muscle lengthening under load and can induce robust skeletal muscle adaptations, including the attenuation of muscle wasting, promotion of myofiber hypertrophy and stimulation of satellite cell activation and proliferation, as previously demonstrated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728513</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728513-s100a8-knockdown-mitigates-symptoms-in-marfan-syndrome</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Muscle-tissue-fiber-detail.webp?t=1709912593" type="image/jpeg" medium="image" fileSize="173605">
        <media:title type="plain">Illustration of muscle anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Sarepta shifts to efficacy outlook with three-year Elevidys DMD data</title>
      <description>
        <![CDATA[After a roller coaster of a year for Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta Therapeutics Inc. looks to focus on the efficacy narrative in 2026, starting with newly unveiled three-year data showing durable efficacy across all key motor function assessments for treated DMD patients vs. external controls.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728315</guid>
      <pubDate>Mon, 26 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728315-sarepta-shifts-to-efficacy-outlook-with-three-year-elevidys-dmd-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/Child-on-bench.webp?t=1769464109" type="image/jpeg" medium="image" fileSize="1003652">
        <media:title type="plain">Child legs dangling from bench</media:title>
      </media:content>
    </item>
    <item>
      <title>Hisamitsu to go private with $2.5B management buyout </title>
      <description>
        <![CDATA[Hisamitsu Pharmaceutical Co. Inc. President and CEO Kazuhide Nakatomi is leading a management buyout to take the company private, citing mounting drug pricing pressures and tougher listing requirements on the Tokyo Stock Exchange.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727775</guid>
      <pubDate>Fri, 09 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727775-hisamitsu-to-go-private-with-25b-management-buyout</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Kazuhide-Nakatomi-president-and-CEO-Hisamitsu-1-9.webp?t=1767984414" type="image/jpeg" medium="image" fileSize="308782">
        <media:title type="plain">Kazuhide Nakatomi, president and CEO, Hisamitsu</media:title>
        <media:description type="plain">Kazuhide Nakatomi, president and CEO, Hisamitsu Pharmaceutical</media:description>
      </media:content>
    </item>
    <item>
      <title>Mereo and Ultragenyx stagger as phase IIIs in brittle bones fail</title>
      <description>
        <![CDATA[Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo Biopharma Group plc’s studies of the monoclonal antibody in treating osteogenesis imperfecta hit statistical significance in their primary endpoints, though they did achieve their secondary endpoints. The companies are still looking at the numbers to determine their next steps.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727382</guid>
      <pubDate>Mon, 29 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727382-mereo-and-ultragenyx-stagger-as-phase-iiis-in-brittle-bones-fail</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Bone-structure-illustration.webp?t=1767044099" type="image/jpeg" medium="image" fileSize="1018017">
        <media:title type="plain">Bone structure illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Gene therapy genie back in the bottle?</title>
      <description>
        <![CDATA[Gene therapy has had its commercial struggles in the past year. The cost to patients is in the millions and fewer are stepping forward for treatment than companies would like. While development continues in this game-changing field, some have struggled with regulatory authorities during development while others have just stepped away altogether.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727374</guid>
      <pubDate>Wed, 24 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727374-gene-therapy-genie-back-in-the-bottle</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gene-therapy-research-pic.webp?t=1588872515" type="image/png" medium="image" fileSize="467422">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact</title>
      <description>
        <![CDATA[Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with Tanabe Pharma Corp. Under the terms, Tanabe will form a new entity harboring both oral and intravenous (I.V.) infusion formulations of edaravone that are marketed in the U.S. as Radicava ORS and I.V. Radicava.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727355</guid>
      <pubDate>Tue, 23 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727355-shionogi-nabs-revenue-generating-als-drugs-with-25b-tanabe-pact</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessman-businesswoman-handshake.webp?t=1707343039" type="image/jpeg" medium="image" fileSize="86464">
        <media:title type="plain">Businessman, businesswoman handshake</media:title>
      </media:content>
    </item>
  </channel>
</rss>
